A Case of Steatocystoma Multiplex in a Psoriatic Patient During Treatment with Anti-IL-12/23
January 2020
in “
Skin Appendage Disorders
”
TLDR Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.
The document reported a case of steatocystoma multiplex (SM) in a psoriatic patient undergoing treatment with ustekinumab, an IL-12/IL-23 inhibitor. SM is characterized by multiple asymptomatic cutaneous cysts and is linked to a mutation in the keratin 17 gene (KRT17). The authors hypothesized that ustekinumab might have revealed a genetic predisposition to SM by reducing the expression of interferon-γ and IL-17/IL-22, thereby affecting the K17 pathway.